SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

"Therapeutic targeting of self-reactive B-cells and antibodies in neurologic disease"

Kevin O'Connor, PhD

Associate Professor of Neurology and Immunobiology, Yale School of Medicine

Tuesday, April 5, 2022 from 4-5 PM
Location: Brady Auditorium BML 131 (hybrid format, also by Zoom)

CME Activity Code: Text 29006 to 203-442-9435

Host: Dr. Jordan Pober
Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Compare and contrast the immunopathology underlying myasthenia gravis disease subtypes.
2. Demonstrate how B cell depletion and complement inhibition treatment strategies leverage key elements of myasthenia gravis immunopathology.
3. Apply an understanding of the divergent myasthenia gravis subtype immunopathology so that prognoses of response-to-treatment can be developed.

FACULTY DISCLOSURES
Kevin O'Connor: Received research support from Cabaletta and Alexion; member of advisory committee/review panel for Roche, Genentech, and Alexion
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.